Avenue therapeutics inc stock. market, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $2. Get real-time Avenue Therapeutics (ATXI) stock price quotes, analyst insights, forecasts, news, and information you need to help your stock trading and investing. Up to 10 years of financial statements. 8 percent on Friday, buoyed by investor optimism following positive drug trial results that position the company favorably in the competitive pharmaceutical landscape. Discover more about Avenue Therapeutics Inc (ATXI) here. 6 million, before deducting underwriting discounts and commissions and View Avenue Therapeutics Inc. ATXI is up 5. This price target corresponds to an upside of 1,842. | Nasdaq ATXI - Avenue Therapeutics Inc - Stock screener for investors and traders, financial visualizations. Apr 23, 2025 · Get a complete stock price history for ATXI (Avenue Therapeutics), starting from its first trading day. Quote News & Events Company Info Financial Info Stock Data SEC Filings Governance 4 days ago · View Avenue Therapeutics, Inc ATXI investment & stock information. (ATXI) growth grade and underlying metrics. (ATXI) stock discussion in Yahoo Finance's forum. S Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the closing of its previously announced public offering of an aggregate of 16,633,400 units (or pre-funded units in lieu Interactive Chart for Avenue Therapeutics, Inc. market, today announced the closing of its public offering of 1,946,787 shares of common stock at a public offering price of $1. 43 percent on Friday, significantly impacted by market sentiment surrounding recent news articles. (ATXI) price, historical values, financial information, price forecast, and insights to empower your investing journey | MSN Money Avenue Therapeutics, Inc. , a Fortress Biotech Company, is a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes products for use in acute healthcare or hospital settings. : Delayed Quote, intraday chart, variations, volumes, technical indicators and last transactions, Stock Avenue Therapeutics, Inc. Nov 14, 2024 · Avenue Therapeutics details Q3 financial results with $2. Annual stock financials by MarketWatch. Quant Ratings, revenue growth, EBITDA, EPS, cash flow, ROE, compounded, charts, and stocks At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. (ATXI) stock analysis with Score, Quality, Valuation, price movements, total returns, financials, shareholding, technicals Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. Avenue expects its common stock Dec 1, 2017 · Find the latest Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and Aug 28, 2025 · Get Avenue Therapeutics, Inc. 09, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) news, including clinical trials, financial reports, and regulatory milestones. 303% today. View ATXI historial stock data and compare to other stocks and exchanges. Find the latest news for Avenue Therapeutics, Inc. View the real-time Avenue Therapeutics Inc (ATXI) stock price. (the “Issuer”), by Fortress Biotech, Inc Apr 2, 2025 · Avenue Therapeutics, Inc. How do I replace them? Our transfer agent, VStock Transfer, LLC, will perform any necessary replacements. View ATXI insider trading, corporate lobbying, Congressional trading, social media sentiment, and more. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. S. 5, collectively, the “Schedule 13D”) relating to the Common Stock of Avenue Therapeutics, Inc. Avenue Therapeutics Inc (NASDAQ:ATXI) stock has tumbled to a 52-week low, touching down at $1. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock. View the latest ATXI financial statements, income statements and financial ratios. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. 83 million and reported a net profit loss of $2 million as of March 2025. (ATXI) stock, including valuation metrics, financial numbers, share information and more. stock was issued. (OTC: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The highest analyst price target is $134. | Deutsche Boerse AG Apr 24, 2024 · MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. listed on the Börse Stuttgart stock exchange. Analysts project positive earnings and revenue trends, suggesting a favorable outlook for the company's stock. 49, and the lowest is $104. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and Mar 7, 2025 · Avenue Therapeutics Inc: * AVENUE THERAPEUTICS INC - ANNJI INTENDS TO TERMINATE LICENSE AGREEMENT WITH CO Further company coverage: Avenue Therapeutics, Inc. (ATXI) stock. (ATXI) income statement. Historical Data News & Events Company Info Financial Info Stock Data SEC Filings Governance NEW YORK, Sept. stock information by Barron's. (US:ATXI) has 3 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Apr 24, 2024 · MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. market, today announced the closing of its public offering of 1,910,100 shares of common stock at a public offering price of $1. 08 - 8. Stay updated on market trends for ATXI. 5 to Schedule 13D (this “Amendment No. has seen its stock price trading down by -5. 855M with 2,053,923 shares outstanding. 34. Sep 11, 2025 · Get the latest Avenue Therapeutics, Inc. (ATXI), analyze all the data with a huge range of indicators. This Amendment No. Aug 21, 2025 · Interactive stock price chart for Avenue Therapeutics, Inc. News. (ATXI) stock price, news, historical charts, analyst ratings and financial information from WSJ. Jan 27, 2023 · MIAMI, Jan. May 5, 2022 · Find the latest historical data for Avenue Therapeutics, Inc. 4 days ago · Complete Avenue Therapeutics Inc. Investors Avenue Therapeutics, Inc. See the latest Avenue Therapeutics Inc stock price (ATXI:PINX), related news, valuation, dividends and more to help you make your investing decisions. Get the latest Avenue Therapeutics, Inc. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor Find the latest Avenue Therapeutics, Inc. Aug 15, 2025 · View real-time stock prices and stock quotes for a full financial overview. The first stock split occurred on September 23, 2022 with the ratio of 1-for-15, meaning that for 15 shares of ATXI owned pre-split, shareholders then owned 1 share. Nov 14, 2024 · Stay updated on Avenue Therapeutics Inc. Aug 5, 2025 · Track AVENUE THERAPEUTICS, INC. Mar 18, 2024 · About Avenue Therapeutics Avenue Therapeutics, Inc. Feb 9, 2025 · Avenue Therapeutics Inc. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. View real-time 49Y stock price and news, along with industry-best analysis. , a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. 40 USD. Common Stock (ATXI) including earnings per share, earnings forecasts at Nasdaq. (OTCPK:ATXI) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Aug 28, 2025 · Explore Avenue Therapeutics stock price, quotes, charts and forecasts with Benzinga. | OTC Markets: ATXI Discover historical prices for ATXI stock on Yahoo Finance. Mar 13, 2025 · Avenue Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. A high-level overview of Avenue Therapeutics, Inc. 07. Includes open, high, low, close and volume. The most influential news is related to Avenue Therapeutics announcing a substantial delay in its new drug approval process, raising investor concerns and contributing to the downturn. Feb 15, 2022 · NEW YORK, Feb. Assess historical data, charts, technical analysis and contribute in the forum. 43, with a market capitalization of just $3. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. Stock analysis for Avenue Therapeutics Inc (ATXI:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U. Share your opinion and gain insight from other stock traders and investors. (ATXI) stock price, news, historical charts, analyst ratings, and quotes on Tiger Brokers' website. Nov 14, 2024 · Avenue Therapeutics, Inc. Mar 18, 2025 · Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and Nov 14, 2024 · Learn more about Avenue Therapeutics Inc's (ATXI) stock grades for Momentum and Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs. Research Avenue Therapeutics' (OTCPK:ATXI) fundamentals, past performance, valuation, dividends and more. Overview Avenue Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. 4 days ago · Detailed statistics for Avenue Therapeutics, Inc. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) with real-time updates, full price history, technical analysis and more. is a pharmaceutical company developing intravenous Tramadol for post-operative pain management. Sep 10, 2025 · Avenue Therapeutics, Inc. Major shareholders Avenue Therapeutics, Inc. It is 6 days ago · Avenue Therapeutics, Inc. Quarterly or annual. The latest Avenue Therapeutics stock prices, stock quotes, news, and ATXI history to help you invest and trade smarter. Discover real-time Avenue Therapeutics Inc. Compare ATXI with the industry and explore the PEG ratio. Smart analysis of ATXI stock. Key Market Happenings Avenue Therapeutics recently reported a significant change in its drug development pipeline, which resulted in increased interest from investors… May 15, 2024 · About Avenue Therapeutics Avenue Therapeutics, Inc. (ATXI) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Find the latest Avenue Therapeutics, Inc. Based on the ratings of 7, the consensus recommendation for ATXI is BUY Mar 20, 2025 · Avenue Therapeutics, Inc. Company Profile Avenue Therapeutics, Inc. View daily, weekly or monthly format back to when Avenue Therapeutics, Inc. (ATXI) stock price with financials, statistics, dividends, charts and more. (ATXI) stock news and headlines to help you in your trading and investing decisions. The range of stock forecasts for ATXI is 8. (49Y:): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Avenue Therapeutics, Inc. 27, representing a +13,153% increase from the current price of $0. (ATXI) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. 61 million. Find the latest Avenue Therapeutics Inc (ATXI) discussion and analysis from iHub's community of investors. Jul 13, 2018 · The average stock forecast for Avenue Therapeutics Inc (ATXI) is 8. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced that it will effect a 1-for-15 reverse split of its common stock, which will be effective for trading Avenue Therapeutics Inc. 22, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. It has a market cap of $0. Financial Results News & Events Company Info Financial Info Stock Data SEC Filings Governance Apr 24, 2024 · Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate Get the latest Avenue Therapeutics, Inc. Nov 12, 2021 · NEW YORK, Nov. 39, and today's volume is 101,545. 5”) amends and supplements the Schedule 13D filed on October 19, 2017 (as amended and supplemented through the date of this Amendment No. Avenue Therapeutics, Inc. 16 USD. May 13, 2025 · Find the latest Avenue Therapeutics, Inc. Find out the 52-week range, trading volume, and market cap. Avenue Therapeutics Inc. Get the latest Avenue Therapeutics, Inc ATXI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Avenue’s lead product candidate is intravenous (IV) tramadol for the management of post-operative pain. Common Stock (ATXI) at Nasdaq. (ATXI)，Yahoo奇摩股市提供您即時報價、個股走勢、成交資訊、當日籌碼，價量變化、個股相關新聞等即時資訊。 Aug 9, 2024 · About Avenue Therapeutics Avenue Therapeutics, Inc. (ATXI). View real-time ATXI stock price and news, along with industry-best analysis. advanced stock charts by MarketWatch. Apr 29, 2024 · MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. Common Stock (ATXI) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq. There may be a fee associated with this service. Mar 28, 2025 · The final output will be presented in user-friendly dashboards, visualizing the forecasted ATXI stock performance trends and incorporating key risk factors. May 2, 2025 · Find the latest Avenue Therapeutics, Inc. | BOERSE MUENCHEN: 49Y Jan 31, 2025 · ATXI Stock Summary Avenue Therapeutics Inc (NASDAQ:ATXI) stock price today is $1. 5 days ago · Check if ATXI Stock has a Buy or Sell Evaluation. (OTCPK:ATXI) dropped from S&P TMI Index Published on 03/20/2025 S&P Capital IQ Avenue Therapeutics, Inc. Profit on the stock market by investing in biotech stocks ATXI - Avenue Therapeutics Inc - Stock screener for investors and traders, financial visualizations. Avenue Therapeutics Inc has split its stock 2 times since its initial public offering (IPO). The gross proceeds of the offering were approximately $2. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and Find out the direct holders, institutional holders and mutual fund holders for Avenue Therapeutics, Inc. (ATXI) financial forecast indicates potential growth in the near term. 4 Million in Gross Proceeds Apr 24, 2024 Avenue Therapeutics Announces Reverse Stock Split Mar 25, 2024 Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 1 2 3 4 5 6 7 8 9 10 arrow_forward Webull offers Avenue Therapeutics Inc (ATXI) historical stock prices, in-depth market analysis, OTCID: ATXI real-time stock quote data, in-depth charts. Find the distribution by types of shareholders of Avenue Therapeutics, Inc. stock price (ATXI), historical data, earnings reports, stock split stock split history, analyst ratings, and forecasts from Perplexity Finance. 86%. The 30 day average volume is 87,901. This model will be a valuable tool to assist in investment decision-making, portfolio management, and risk assessment for Avenue Therapeutics Inc. Get the latest ATXI - AVENUE THERAPEUTICS INC quote information including top holdings and analyst ratings. View as % YoY growth or as % of revenue. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases (“CNS”), today reported financial results and recent corporate highlights for the third quarter ended September 30, 2022 Avenue Therapeutics Inc (ATXI) stock price, GURU trades, performance, financial stability, valuations, and filing info from GuruFocus. View now. Get Avenue Therapeutics Inc news, earnings, and stock analysis — all in one place at TipRanks. Oct 11, 2022 · Avenue expects to use the net proceeds from the offering, together with its existing cash, to repurchase all of the shares of its common stock held by InvaGen Pharmaceuticals Inc. Complete Avenue Therapeutics Inc. Over the years, the company’s innovative approach to drug development, strategic realignments, and dedication to addressing unmet medical needs have made its common stock a point of interest for investors and industry observers alike. View real-time Avenue Therapeutics (ATXI) live share price and historical data, charts, technical analysis, financial reports and other OTC:ATXI stock data today. Avenue expects its common stock NEW YORK, Nov. ATXI analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Stay up-to-date on Avenue Therapeutics, Inc. Get real-time Avenue Therapeutics Inc (ATXI) stock price, news, financials, community insights, and trading ideas. I've moved. 90. (ATXI:): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Avenue Therapeutics, Inc. Avenue Therapeutics Inc (ATXI) Stock Price, Chart, Latest News, Technical Indicator, Option Chain and much more. 06. (Nasdaq: ATXI) has forged a unique path in the competitive biotechnology and pharmaceutical landscape. Sep 16, 2025 · Should You Buy or Sell Avenue Therapeutics Stock? Get The Latest ATXI Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. This article chronicles the Nov 2, 2023 · MIAMI, Nov. View the latest Avenue Therapeutics Inc. Dec 15, 2021 · NEW YORK, Dec. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor Jul 12, 2024 · Avenue Therapeutics, Inc. I've lost my stock certificates. 0 million Nov 14, 2024 · About Avenue Therapeutics Avenue Therapeutics, Inc. Aug 29, 2025 · Get the latest news and real-time alerts from Avenue Therapeutics, Inc. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor Jan 27, 2025 · Avenue Therapeutics Inc (NASDAQ: ATXI) stock has tumbled to a 52-week low, touching down at $1. Common Stock (ATXI) Dividends, Current Yield, Historical Dividend Performance, and Payment Schedule. The most recent stock split took place on April 26, 2024 on a 1-for-75 basis. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small Avenue Therapeutics Inc. NEW YORK, Nov. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. Aug 9, 2024 · MIAMI, Aug. Nov 10, 2022 · NEW YORK, Nov. Avenue Therapeutics Inc is a specialty pharmaceutical innovator focused on IV Tramadol, AJ201, and BAER-101, delivering balanced therapies for pain and neurologic conditions. View (ATXI) real-time stock price, chart, news, analysis, analyst reviews and more. 6 million Get the latest stock price history, news, and analysis for Avenue Therapeutics Inc (ATXI). 15, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. Get the latest Avenue Therapeutics Inc (ATXI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. . Create real-time notifications to follow any changes in the live stock price. The Avenue Therapeutics Inc (ATXI) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $119. , with the Mar 18, 2024 · MIAMI, March 18, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. Discover the geographical origin of the shareholders of Avenue Therapeutics, Inc. The Company is advancing a diverse portfolio that includes first-in-class and best-in-class programs in a high-value neurologic landscape with significant unmet patient need. View today's Avenue Therapeutics Inc stock price and latest ATXI news and analysis. Sustained progress in key clinical trials and market acceptance of innovative therapies will be crucial for long-term success. Market Insights: A recent […] Nov 14, 2024 · Apr 29, 2024 Avenue Therapeutics Announces Exercise of Warrants for $4. How do I notify the Company of my new address? Stockholder address changes must be submitted to the transfer agent, VStock Transfer, LLC. ATXI market cap is 2. 3 days ago · Get undefined (ATXI. market Sep 22, 2022 · Find the latest press releases from Avenue Therapeutics, Inc. Jun 22, 2025 · Comprehensive Avenue Therapeutics, Inc. ATXI Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Avenue Therapeutics, Inc. NEW YORK, Dec. Sep 5, 2025 · What's going on at Avenue Therapeutics (NASDAQ:ATXI)? Read today's ATXI news from trusted media outlets at MarketBeat. Key data expected end-2024. (ATXI) stock at Seeking Alpha. Trade with advanced market insights on Tiger Trade app. 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (49Y:FRA): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Avenue Therapeutics, Inc. (ATXI) stock quote, history, news and other vital information to help you with your stock trading and investing. Feb 8, 2015 · Avenue Therapeutics, Inc. Common Stock. InvestingPro analysis shows the company Dec 24, 2024 · Find the latest SEC Filings data for Avenue Therapeutics, Inc. Find annual and quearterly earnings data for Avenue Therapeutics, Inc. 0 million Nov 14, 2024 · MIAMI, Nov. Stay ahead with Nasdaq. is seeing its shares trade up by 3. Common Stock (ATXI) including 10-K and 10-Q forms at Nasdaq. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U. com. Stock on our page and stay on top of the game. May 23, 2025 · See what signals are being triggered and find all the latest price data and stock quotes for the ATXI stock. ATXI stock data, price, and news. 6M cash position, increased R&D spending, and progress on AJ201 trial for muscular atrophy. Your central hub for ATXI developments. 10, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. Largest shareholders include . Jan 24, 2025 · Avenue Therapeutics Inc. Find the latest Avenue Therapeutics, Inc. Jan 23, 2025 · Stay up-to-date on Avenue Therapeutics, Inc. , a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Stock analysis for Avenue Therapeutics Inc (49Y0:GR) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Track ATXI Stock with real-time price updates, overview, analysis, insider insights, and Smart Score ratings. hywwqj lbkbw vudbtg odohpsmx kik grj abglmx kzx vargz ljg